DexCom has had a rough ride this year. The medical technology company is grappling with concerns about its slowing growth and allegations of faulty blood glucose monitors. However, DexCom is “already ...
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. DexCom made certain product changes without FDA authorization. The Company's product changes ...
DexCom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of Dexcom Academy, a new personalised learning ...
As previously reported, Morgan Stanley upgraded DexCom (DXCM) to Overweight from Equal Weight with a price target of $75, up from $63, citing signs that the company is already turning the corner from ...
China’s XPeng has detailed its new vehicle launch plans for 2026. The updated XPeng G6 electric mid-size SUV, fresh from receiving Australian Design Rule (ADR) compliance, is confirmed for a local ...
RECALL ALERT: There are 7 recalls on this vehicle. Learn More. There are 7 recalls on this vehicle. Learn More. RECALL ALERT: There are 7 recalls on this vehicle. Learn More. There are 7 recalls on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback